Corporate Overview Jefferies Global Healthcare Conference

June 4, 2014

NASDAQ: CYTR

1

CytRx Safe Harbor Statement

THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE COMPANY. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF THE RISK FACTORS DISCUSSED IN CYTRX REPORTS ON FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION INCLUDING, BUT NOT LIMITED TO, THE REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2013, AND FORM 10-Q FOR THE QUARTER ENDED MARCH 31,2014.

2

Corporate Snapshot

Proprietary world-class albumin-binding technology with demonstrated clinical efficacy

Pivotal Phase 3 trial with SPA is underway

Drug discovery operations established in Freiburg, Germany

Phase 2b results announced: Aldoxorubicin shows significantly improved

efficacy over doxorubicin in 1st-line soft tissue sarcoma

3

Why Albumin-Binding Conjugates?

Large market potential targeting most common cancers

Accumulation and selective release of drug conjugates bound to albumin in solid tumors allows delivery of 3-5x higher drug doses and increased antitumor efficacy (preclinical and clinical results)

Potential to improve both Quality of Life and Overall Survival Benefit (Aldoxorubicin)

Unique Platform Technology

4

CytRx R&D Lab in Freiburg

Creation of a continuous pipeline

Design of new albumin-binding drug conjugates

Optimization of their stability and cleavage

properties

Formulation of the finished product

Co-ordination of all biological investigations

and rapidly moving the drug conjugates from

bench to the clinic

drug

5

Aldoxorubicin Clinical Development Program

Aldoxorubicin (delivery-enhanced doxorubicin) Preclinical Phase 1 Phase 2 Phase 3

2nd-line Soft Tissue Sarcoma (STS)

1st- Line Soft Tissue Sarcoma

Glioblastoma Multiforme (GBM)

Kaposi’s Sarcoma

Small Cell Lung Cancer

Pharmacokinetic Study

Combo with gemcitabine

Combo with ifosfamide

Phase 2 on-going

Phase 2b on-going

Phase 3 on-going

Phase 1 completed

Top-line Data announced

Phase 2 on-going

Phase 2b to start Q3 2014

Ph 1 in planning

Ph 1 in planning

6

Aldoxorubicin

First and only single agent to substantially surpass doxorubicin in STS

80-100% superiority over doxorubicin in progression-free survival in 1st-line STS

Orphan drug status for STS granted in the USA and EU

Broad potential to treat solid and hematological tumors

Worldwide exclusive license from KTB Tumorforschungs GmbH in Freiburg, Germany

7

Mechanism of Aldoxorubicin

Drug / linker conjugate is infused into the patient Tumor cells

Albumin transports drug to the tumor

Linker dissolves in the acidic (low pH) environment, releasing the drug payload

Linker rapidly binds conjugate to albumin

1

2

3

4

Dox Linker

Dox Linker Albumin

Aldoxorubicin allows for 3.5x the standard dose of doxorubicin at each cycle

8

Aldoxorubicin First-line STS Phase 2b Trial Design

Screened N=140

2:1 Randomization N=123

Aldoxorubicin 350mg/m2

(260mg/m2 dox equiv.) Every 3wk up to 6 cycles

N=83

Doxorubicin 75mg/m2

Every 3wk up to 6 cycles N=40

3 subjects randomized but not

dosed

14 screen failures

CT Scans every 6 weeks

9

Patient Characteristics

Characteristics Aldoxorubicin Doxorubicin

N 83 40

Age, median (range) 54.0 (21-77) 54.0 (23-77)

Male / Female, n (%) 38 (46) / 45 (54) 18 (45) / 22 (55)

Race, n (%)

Caucasian 61 (74) 32 (80)

Black or African American 1 (1) 1 (2.5)

Asian 16 (19) 6 (15)

Other 5 (6) 1 (2.5)

ECOG, n (%)

0-1 80 (96.4) 37 (92.5)

2 3 (3.6) 3 (7.5)

Completed Cycles, median (range) 6 (1-6) 4 (1-6)

10

Phase 2b Trial Efficacy Endpoints

Primary Endpoint: Progression-Free Survival

Secondary Endpoints −Progression-free survival at 6 months −Overall Response Rate (Complete and Partial) −Overall Survival – still on-going; expect 2H14

CT Scans every six weeks

Endpoints assessed using RECIST 1.1 criteria −Locally by investigator −Independent radiography review at central lab blinded to

subjects’ treatments

11

PFS Results

All Subjects

Intent-to-treat P Value

Scans Read by Investigator

Aldoxorubicin 8.4 months P=0.0004

Doxorubicin 4.7 months

Improvement over dox 3.7 mos. (79%)

Hazard ratio 0.419 (0.25-0.69) P=0.0007

Scans Read by Central Lab

Aldoxorubicin 5.7 months P=0.014

Doxorubicin 2.8 months

Improvement over dox 2.9 mos. (104%)

Hazard ratio 0.584 (0.37-0.93) P=0.024

12

Kaplan-Meier Analysis of Progression-Free Survival Investigator Assessment

3.7 month improvement

HR: 0.419, p=0.0007

13

Kaplan-Meier Analysis of Progression-Free Survival Central Radiology Lab Review

2.9 month improvement

HR: 0.584, p=0.024

14

PFS at 6 Months Results

All Subjects

Intent-to-Treat P Value

Scans Read by Investigator

Aldoxorubicin 68.1% P=0.002

Doxorubicin 36.6%

Improvement over dox 86.1%

Scans Read by Central Lab

Aldoxorubicin 45.7% P=0.02

Doxorubicin 22.9%

Improvement over dox 99.6%

15

Overall Response Rate Results

Aldoxorubicin Doxorubicin

Scans Read by Investigator

Complete Response 2.4% 0%

Partial Response 19.3% 5.0%

Overall Response Rate 21.7% 5.0%

Scans Read by Central Lab

Complete Response 0% 0%

Partial Response 23.8% 0%

Overall Response Rate 23.8% 0%

16

Waterfall Plot - Investigator

Aldoxorubicin

64.5% had tumor shrinkage

Doxorubicin

41.2% had tumor shrinkage

17

Waterfall Plot – Blinded Central Lab

Aldoxorubicin

60.8% had tumor shrinkage

Doxorubicin

39.4% had tumor shrinkage

18

Comparison to Current STS Treatments

CytRx Phase 2b

Investigator assessed

EORTC Phase 3

Dox vs. dox+ ifosfamide

Aldox Dox Dox+ ifos Dox

N 83 40 215 217

Age 54 (21-77) 54 (23-77) 48 (18-60) 47 (18-63)

PFS (months) 8.4 4.7 7.4 4.6

P value 0.0007 0.003

ORR 21.7% 5.0% 26.5% 13.6%

19

Phase 2b: Safety Data

Adverse events were consistent with known doxorubicin toxicities

Grade 3 or 4 neutropenia, mucositis and nausea/vomiting are higher in aldoxorubicin-treated subjects but are not treatment limiting

Aldoxorubicin treated subjects received more than 5 times the cumulative amount of doxorubicin in this study than the doxorubicin subjects without any evidence of clinically relevant decreased left ventricular ejection fraction (LVEF), and in more instances an increase in LVEF, either by MUGA or echocardiogram.

~6% of doxorubicin patients had clinically significant cardiotoxicity

20

Ph 3 Trial in 2nd-Line STS

Randomized, Comparative Trial Design with SPA −Special Protocol Assessment (SPA) granted by FDA −SPA allows for dosing until disease progression −Trial underway; actively enrolling now at numerous sites

Patient Population −400 STS patients that have progressed following treatment

with chemotherapy −Up to 5 prior cycles or 375mg/m2 of doxorubicin or liposomal

doxorubicin equivalents allowed

Endpoints −Primary: Progression Free Survival −Secondary: Overall survival, response rates, safety, etc.

21

Phase 3 Trial Design: 2nd-line STS

Soft tissue sarcoma patients that have relapsed or are refractory to prior chemotherapy

1:1 Randomization N=400

Aldoxorubicin 350mg/m2

(260mg/m2 dox equiv.) Every 3weeks until disease progression

N=200

Physicians Choice: Doxorubicin Dacarbazine Ifosfamide

Gemcitabine+docetaxel Pazopanib

N=200

CT Scans every 6 weeks

22

Aldoxorubicin Efficacy in 2nd-line STS

-60

-50

-40

-30

-20

-10

0

10

20

30

40

* Indicates prior therapy with doxorubicin, epirubicin or Doxil®

*

*

*

* *

*

*

Ch

an

ge F

ro

m B

aselin

e in

Su

m o

f D

iam

ete

r

Tu

mo

r M

easu

rem

en

t (%

)

Phase 1b/2: Best Response of the 13 Evaluable STS Patients Treated at 350 mg/m2

PFS = 11.3 months OS = 21.7 months ORR = 38%

23

Glioblastoma Multiforme (GBM)

GBM is one of the most frequent adult primary brain tumors

Affects 12,500 new patients in the U.S. annually

Median survival is 14 months despite current standard of care treatment including surgery, radiotherapy and chemotherapy with temozolomide

5 year survival: ~4%

GBM

GBM

24

Aldoxorubicin significantly improves survival in vivo

Dox: dashed green Vehicle: dashed red

Survival benefit confirmed in three animal studies

− Aldoxorubicin increased lifespan in orthotopic xenograft mouse model with intracranial implanted human GBM cells versus doxorubicin and saline

− Aldoxorubicin crosses the blood-brain barrier. Doxorubicin does not

− Demonstrated that aldoxorubicin accumulates in the brain tumor and not in healthy brain tissue

Phase 2 trial enrolling

− Evaluating aldoxorubicin as a treatment in late-stage glioblastoma multiforme following surgery, radiation and chemotherapy

− Patients to be treated until progression

Aldox treated

P<0.0001

Preclinical GBM results presented at the ESMO Meeting on September 30, 2013

25

Aldoxorubicin accumulates in the tumor and not in healthy brain tissue

Doxorubicin does not enter the brain

Dox+ Aldox+

Tumor

Tumor

Healthy brain tissue

Healthy brain tissue

Aldoxorubicin enters brain and delivers

dox to tumor

26

2Q15: Results from Ph 2 Kaposi’s Sarcoma trial

2H15: Complete enrollment in Ph 3 STS trial

2H15: Start Ph 1 new conjugate

4Q15: Results from Ph 1 combo trials expected

Ph 2 Kaposi’s Sarcoma trial initiated

Initiated Ph 3 clinical trial in 2nd-line soft tissue sarcoma

Oral presentation of Ph 2b STS results at ASCO Annual Meeting

2H14: Initiate Phase 2b 2nd-line SCLC trial

2H14: Preliminary Phase 2 GBM results expected

2H14: OS data expected from Phase 2b 1st-line STS trial

2014

Expected Upcoming Catalysts

2015 2016

2Q16: Ph 3 STS PFS data

4Q16: NDA filing in STS

2H16: Ph 2b 2nd-line SCLC data expected

2017: NDA approval for aldoxorubicin in STS

2017

27

Financial Summary

Balance sheet (as of 3/31/14) −Cash: $112.6M −Debt: $ 0.0M

Shares Outstanding 55.8M

Options 6.7M −Average strike price: $3.20

Warrants 7.9M −Average strike price: $4.80

28

Conclusion

Aldoxorubicin demonstrates superiority to doxorubicin − Achieved highly statistically significant results on all efficacy endpoints − Potential to replace doxorubicin for treating many types of cancer

Novel delivery platform with broad applicability − Improves efficacy and side-effect profiles of known chemotherapy drugs − Provides potential partnership opportunities for anti-cancer agents that are

losing patent protection

Late-stage pipeline with near-term clinical catalysts − Phase 3 with SPA as 2nd-line treatment for STS is enrolling − Phase 2 trials in glioblastoma and HIV-related Kaposi’s sarcoma are enrolling − Phase 2b 1st-line STS overall survival results expected 2H14 − Phase 2b 2nd-line SCLC trial planned start in 3Q14 − Phase 1 combination trials to start in 2H14

Risk-mitigated strategy − Creates potential blockbuster oncology therapies with known chemotherapy

payloads